Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.71 |
| ▸ | HPGD | P15428 | 6/20 | 0.71 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.71 |
| ▸ | USP2 | O75604 | 1/20 | 0.67 |
| ▸ | TSHR | P16473 | 1/20 | 0.67 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.62 |
| ▸ | POLB | P06746 | 1/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 3/20 | 0.56 |
| ▸ | TP53 | P04637 | 2/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | RECQL | P46063 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14546704 | 0.89 | HPGD (0.67) | ALDH1A1HPGDKDM4EUSP2TSHR | |
| SCHEMBL2459924 | 0.89 | ALDH1A1 (0.67) | ALDH1A1HPGDKDM4EUSP2TSHR | |
| SCHEMBL2459553 | 0.87 | HPGD (0.65) | ALDH1A1HPGDKDM4EUSP2TSHR | |
| SCHEMBL2457455 | 0.87 | HPGD (0.65) | ALDH1A1HPGDKDM4EUSP2TSHR | |
| SCHEMBL2457789 | 0.85 | ALDH1A1 (0.60) | ALDH1A1HPGDKDM4EUSP2TSHR | |
| SCHEMBL2459373 | 0.84 | ALDH1A1 (0.66) | ALDH1A1HPGDKDM4EUSP2TSHR | |
| SCHEMBL2466786 | 0.84 | ALDH1A1 (0.62) | ALDH1A1HPGDKDM4EUSP2TSHR | |
| SCHEMBL9901617 | 0.83 | ALDH1A1 (1.00) | ALDH1A1HPGDKDM4EUSP2TSHR | |
| SCHEMBL2462187 | 0.83 | ALDH1A1 (0.65) | ALDH1A1HPGDKDM4EUSP2TSHR | |
| SCHEMBL2461341 | 0.82 | ALDH1A1 (0.64) | ALDH1A1HPGDKDM4EUSP2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8372851-B2 | Pyrazolo pyrimidines as casein kinase II (CK2) modulators | EXELIXIS, INC. (US) | 2013-02-12 | — | — | US | claimed |
| EP-1948663-B1 | PYRAZOLO-PYRIMIDINES AS CASEIN KINASE II (CK2) MODULATORS | EXELIXIS INC (US) | 2011-09-14 | — | — | EP | claimed |
| US-20100130488-A1 | Pyrazolo-Pyrimidines as Casein Kinase II (CK2) Modulators | EXELIXIS, INC. | 2010-05-27 | — | — | US | claimed |
| EP-1948663-A2 | PYRAZOLO-PYRIMIDINES AS CASEIN KINASE II (CK2) MODULATORS | Exelixis, Inc. (US) | 2008-07-30 | — | — | EP | claimed |
| WO-2007048066-A2 | PYRAZOLO-PYRIMIDINES AS CASEIN KINASE II (CK2) MODULATORS | EXELIXIS, INC. (US) | 2007-04-26 | — | — | WO | claimed |
| US-8372851-B2 | Pyrazolo pyrimidines as casein kinase II (CK2) modulators | EXELIXIS, INC. (US) | 2013-02-12 | — | — | US | disclosed |
| US-8372851-B2 | Pyrazolo pyrimidines as casein kinase II (CK2) modulators | EXELIXIS, INC. (US) | 2013-02-12 | — | — | US | disclosed |
| US-8372851-B2 | Pyrazolo pyrimidines as casein kinase II (CK2) modulators | EXELIXIS, INC. (US) | 2013-02-12 | — | — | US | disclosed |
| EP-1948663-B1 | PYRAZOLO-PYRIMIDINES AS CASEIN KINASE II (CK2) MODULATORS | EXELIXIS INC (US) | 2011-09-14 | — | — | EP | disclosed |
| EP-1948663-B1 | PYRAZOLO-PYRIMIDINES AS CASEIN KINASE II (CK2) MODULATORS | EXELIXIS INC (US) | 2011-09-14 | — | — | EP | disclosed |
| US-20100130488-A1 | Pyrazolo-Pyrimidines as Casein Kinase II (CK2) Modulators | EXELIXIS, INC. | 2010-05-27 | — | — | US | disclosed |
| US-20100130488-A1 | Pyrazolo-Pyrimidines as Casein Kinase II (CK2) Modulators | EXELIXIS, INC. | 2010-05-27 | — | — | US | disclosed |
| US-20100130488-A1 | Pyrazolo-Pyrimidines as Casein Kinase II (CK2) Modulators | EXELIXIS, INC. | 2010-05-27 | — | — | US | disclosed |
| EP-1948663-A2 | PYRAZOLO-PYRIMIDINES AS CASEIN KINASE II (CK2) MODULATORS | Exelixis, Inc. (US) | 2008-07-30 | — | — | EP | disclosed |
| WO-2007048066-A2 | PYRAZOLO-PYRIMIDINES AS CASEIN KINASE II (CK2) MODULATORS | EXELIXIS, INC. (US) | 2007-04-26 | — | — | WO | disclosed |
| WO-2007048066-A2 | PYRAZOLO-PYRIMIDINES AS CASEIN KINASE II (CK2) MODULATORS | EXELIXIS, INC. (US) | 2007-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130488-A1 | Pyrazolo-Pyrimidines as Casein Kinase II (CK2) Modulators | CSNK1A1, CSNK2A1, CSNK2A2 | ALDH1A1 4176/4885HPGD 3821/4885KDM4E 2885/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.